These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29262899)

  • 1. [Icaritin Reverses Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].
    Li ZY; Li ZJ; Chen X; Huang XR; Fang ZQ; Zhang JG; Fang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1690-1695. PubMed ID: 29262899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of Bushen Yanggu Decoction on Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].
    Li YP; Zhang JG; Fang ZQ; Huang XR; Chen X; Li ZJ; Fang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):482-488. PubMed ID: 30998158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway].
    Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.
    Wang L; Cao J; Tao J; Liang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):277-286. PubMed ID: 37642368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
    Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
    Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting Glutaminolysis to Treat Multiple Myeloma: An
    Li C; Feng Y; Wang W; Xu L; Zhang M; Yao Y; Wu X; Zhang Q; Huang W; Wang X; Li X; Ying P; Shang L
    Anticancer Agents Med Chem; 2023; 23(7):779-785. PubMed ID: 36065917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor Activity of Asiaticoside Against Multiple Myeloma Drug-Resistant Cancer Cells Is Mediated by Autophagy Induction, Activation of Effector Caspases, and Inhibition of Cell Migration, Invasion, and STAT-3 Signaling Pathway.
    Yingchun L; Huihan W; Rong Z; Guojun Z; Ying Y; Zhuogang L
    Med Sci Monit; 2019 Feb; 25():1355-1361. PubMed ID: 30785126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
    Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
    Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy].
    Liu LT; Deng SH; Zang MR; Zhang JQ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):583-588. PubMed ID: 32810966
    [No Abstract]   [Full Text] [Related]  

  • 14. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
    Xu P; Jiang YF; Wang JH
    Int J Clin Exp Pathol; 2015; 8(3):2300-10. PubMed ID: 26045737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of bortezomib on MAPK signaling pathway of K562/DNR cells].
    Liao AJ; Fu BB; Wang HH; Li YC; Yao K; Zhang R; Yang W; Liu ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1460-3. PubMed ID: 21176351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
    Ge QF; Ouyang GF; Chen Y; Zhang Y; Mu QT; Lu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):112-5. PubMed ID: 22391178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arsenic trioxide enhances the effects of bortezomib, dexamethasone on multiple myeloma cell line KM3 in vitro.].
    Ouyang GF; Lin MF
    Zhonghua Xue Ye Xue Za Zhi; 2010 Apr; 31(4):240-3. PubMed ID: 20510040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
    Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
    J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.